Get started
Author

Federico Pirrò

Observed names: F Pirro, F. Pirro, Federico Pirro, PIRRO, Federico, Pirro, Federico, Pirro, Federico 1946-
ORCID: 0000-0001-6629-9613
Observed ORCID: 0000-0001-6629-9613
OpenAlex ID: A5005637384
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study
2021 · Federico Pirro, Giacomo Caldarola, et al. · Clinical Drug Investigation · 105
PDF
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature
2020 · G. Caldarola, F. Pirro, et al. · Expert Opinion on Biological Therapy · 100
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
2022 · Tiago Torres, Luis Puig, et al. · American Journal of Clinical Dermatology · 91
A case of guttate psoriasis during treatment with dupilumab
2019 · Niccolò Gori, Giacomo Caldarola, et al. · Dermatologic Therapy · 31
PDF
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
2021 · M Galluzzo, G Caldarola, et al. · Expert Opinion on Biological Therapy · 28
PDF
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice
2020 · Giacomo Caldarola, Marco Mariani, et al. · Expert Opinion on Biological Therapy · 24
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis
2020 · Dario F. D'Urso, Andrea Chiricozzi, et al. · Giornale Italiano di Dermatologia e Venereologia · 24
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies
2020 · Federico Pirro, Giacomo Caldarola, et al. · Journal of Dermatological Treatment · 24
Multiple paradoxical reactions during ixekizumab therapy
2019 · Federico Pirro, Giacomo Caldarola, et al. · Dermatologic Therapy · 23
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study
2022 · Giovanni Pellacani, Laura Bigi, et al. · Journal of Clinical Medicine · 22
PDF
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy
2021 · Arianna Zangrilli, Giacomo Caldarola, et al. · Expert Opinion on Biological Therapy · 8
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross‐sectional study
2021 · Maria Esposito, Alessandro Giunta, et al. · Dermatologic Therapy · 8
Knowledge of HIV infection and transmission: a knowledge, attitudes, beliefs and practices (KABP) survey among a sample of students at the "Magna Graecia", University of Catanzaro.
2016 · Maria Mazzitelli, Giulio Caridà, et al. · Annali dell Istituto Superiore di Sanità · 8
PDF
Risk of infections in psoriasis: assessment and challenges in daily management
2021 · Clara De Simone, Maria Concetta Fargnoli, et al. · Expert Review of Clinical Immunology · 4
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
2025 · Federico Pirro, Giacomo Caldarola, et al. · Dermatology Practical & Conceptual · 1
PDF
Dermatologic Diseases: Psoriasis and Psoriatic Arthritis
2023 · Andrea Chiricozzi, Federico Pirro · Springer eBooks
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice
2021 · Caldarola, Giacomo, Mariani, Marco, et al. · Figshare
Guillain–Barré Syndrome Associated with COVID-19
2020 · Professor Sir George Alberti, Sandro Beretta, et al. · BOA (University of Milano-Bicocca)
Works count: 45
Citation count: 501
H-index: 10
I10-index: 10
Year
Topic
Type